Abstract
Background: The beneficial effects of spironolactone on the treatment of cardiovascular diseases are well known, but translating these benefits into private practice can be difficult because of the drug's side‐effect profile.
Hypothesis: When patients are monitored over the long term, spironolactone can be used safely with an acceptable side‐effect profile.
Methods: We retrospectively studied 762 patients taking spironolactone over a 7‐year period in a cardiologist's referral‐based practice and monitored them for side effects from the medication.
Results: Data were available on 762 patients. The average age of our patients when started on the medication was 67.2 ±0.5 years. Of these, 585 (76.8%) patients were treated for heart failure and 155 (20.3%) for hypertension. An average dose of 3 8.4 ± 1.4 mg of spironolactone was used for treatment of all conditions. Of the 762 patients, 81 (10.6%) experienced side effects while using the medication; 40 had hyperkalemia (5.3%), 14 had gynecomastia (1.8%), and 15 had gastritis (2%). Of the patients with hyperkalemia, average creatinine clearance decreased from 64.6 ±5.8 ml/min at therapy start to 50.3 ±5.5 ml/min at the time of onset of side effects.
Conclusion: Spironolactone can be used with an acceptable side‐effect profile as long as patients are monitored long‐term while receiving the medication.
Keywords: spironolactone, eplerenone, hyperkalemia, congestive heart failure, mineralocorticoid, gynecomastia, gastritis, creatinine clearance
Full Text
The Full Text of this article is available as a PDF (34.2 KB).
References
- 1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for The Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341 (10): 709–717 [DOI] [PubMed] [Google Scholar]
- 2. Biykem B, Ildiko A, Knowlton AA: Complications of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41 (2): 211–214 [DOI] [PubMed] [Google Scholar]
- 3. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 5435–5451 [DOI] [PubMed] [Google Scholar]
- 4. Tang WHW, Francis GS: Spironolactone in chronic heart failure: All's well that ends well. J Am Coll Cardiol 2003; 41 (2): 215–216 [DOI] [PubMed] [Google Scholar]
- 5. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31–14 [DOI] [PubMed] [Google Scholar]
- 6. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689–1697 [DOI] [PubMed] [Google Scholar]
- 7. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group : Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82 (5): 1730–1736 [DOI] [PubMed] [Google Scholar]
- 8. Brown NJ: Eplerenone: Cardiovascular protection. Circulation 2003; 107 (19): 2512–2518 [DOI] [PubMed] [Google Scholar]
- 9. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A: Rise in plasma concentration of aldosterone during long‐term angiotensin II suppression. J Endocrinol 1981; 91 (3): 457–465 [DOI] [PubMed] [Google Scholar]
- 10. Jackson E: Diuretics In Goodman and Gillman's The Pharmacological Basis of Therapeutics, 10th edition (Eds. Hardman J, Limburd L.), pp. 779–781. New York: McGraw Hill; [Google Scholar]
- 11. G. D. Searle LLC (subsidiary of Pfizer) . New Inspra Eplerenone Tablets. Annotated prescribing information. 10/15/ 2003.
- 12. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321; [DOI] [PubMed] [Google Scholar]; correction published: N Engl J Med 2003; 348 (22): 2271 [Google Scholar]
- 13. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101 (6): 594–597 [DOI] [PubMed] [Google Scholar]
- 14. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Bridhetti G, Marino P, Zardini P: Long‐term, dose‐dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002; 40 (2): 304–310 [DOI] [PubMed] [Google Scholar]
- 15. Ramires FJ, Mansur A, Coelho O, Maranhao M, Gruppi CJ, Mady C, Ramires JAF: Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000; 85 (10): 1207–1211 [DOI] [PubMed] [Google Scholar]
- 16. Zannad F, Alla F, Dousset B, Perez A, Pitt B, on behalf of the RALES Invesigators : Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000; 102: 2700–2706; [DOI] [PubMed] [Google Scholar]; correction published Circulation 2001; 103 (3): 476 [Google Scholar]
- 17. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M: Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41 (4): 574–581 [DOI] [PubMed] [Google Scholar]
- 18. Schepkens H, Vanholder R, Billiouw JM, Lameire N: Life‐threatening hyperkalemia during combined therapy with angiotensin‐converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 2001; 110 (6): 438–441 [DOI] [PubMed] [Google Scholar]